Generic placeholder image

Current Nanoscience

Editor-in-Chief

ISSN (Print): 1573-4137
ISSN (Online): 1875-6786

Improved Bioavailability of Albendazole Following Oral Administration of Nanosuspension in Rats

Author(s): Mittapalli Pavan Kumar, Yamasani Madhusudan Rao and Shashank Apte

Volume 3, Issue 2, 2007

Page: [191 - 194] Pages: 4

DOI: 10.2174/157341307780619224

Price: $65

Abstract

Albendazole, a lipophilic anthelmintic drug, has low solubility and bioavailability. Albendazole nanosuspensions (ABZNS) were developed using different surfactants (Polysorbate 80 & Poloxamer 188) and hydrophilic mucoadhesive polymers (Hydroxypropyl Methylcellulose) by pre-homogenization followed by high pressure homogenization. Particle size and charge measurements were made with a Malvern Zetasizer. Pharmacokinetics of optimized albendazole nanosuspensions after oral administration to conscious Wistar rats was studied. Average size and zeta potential of optimized formulations of albendazole nanosuspensions ranged from 385.7± 4.3 to 576.2 ± 4.8 nm and - 23.5 ± 1.8 to - 40.5 ± 0.8 mV, respectively. Bioavailability of albendazole nanosuspensions was 2.14 to 2.96 fold after oral administration compared with that of control suspension. These results indicate the potential of nanosuspension in improvement of oral bioavailability of lipophilic drugs such as albendazole.

Keywords: Albendazole, Nanosuspensions, Pharmacokinetics, Bioavailability

« Previous

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy